Analyst Price Targets — OMCL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 29, 2026 1:29 pm | — | Craig-Hallum | $55.00 | $44.45 | TheFly | Omnicell price target raised to $55 from $53 at Craig-Hallum |
| April 28, 2026 5:10 pm | — | KeyBanc | $70.00 | $44.31 | TheFly | Omnicell price target raised to $70 from $60 at KeyBanc |
| March 13, 2026 11:14 am | — | UBS | $60.00 | $35.10 | StreetInsider | Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet |
| February 6, 2026 11:55 am | — | Piper Sandler | $49.00 | $39.08 | TheFly | Omnicell price target lowered to $49 from $63 at Piper Sandler |
| January 16, 2026 10:15 am | — | UBS | $53.00 | $50.98 | StreetInsider | Omnicell (OMCL) PT Raised to $53 at BofA Securities |
| January 7, 2026 10:47 pm | — | KeyBanc | $60.00 | $47.45 | TheFly | Omnicell upgraded to Overweight from Sector Weight at KeyBanc |
| January 5, 2026 1:08 pm | — | Wells Fargo | $52.00 | $45.64 | TheFly | Omnicell price target raised to $52 from $43 at Wells Fargo |
| August 11, 2025 12:26 pm | Jessica Tassan | Piper Sandler | $55.00 | $31.11 | StreetInsider | Omnicell (OMCL) PT Lowered to $55 at Piper Sandler Despite Guide Raise |
| May 14, 2025 10:48 am | Stan Berenshteyn | Wells Fargo | $35.00 | $27.46 | TheFly | Omnicell upgraded to Overweight from Equal Weight at Wells Fargo |
| January 13, 2025 11:06 am | Stan Berenshteyn | Wells Fargo | $40.00 | $43.37 | TheFly | Omnicell price target lowered to $40 from $49 at Wells Fargo |
Latest News for OMCL
Omnicell is advancing its autonomous pharmacy vision and expanding SaaS offerings, but tariffs and fierce competition could test its growth path.
Shares of Omnicell OMCL have rallied 52.6% over the past year, significantly outperforming the industry's 20.8% fall and the S&P 500 composite's 23.9% gain.
FORT WORTH, Texas--(BUSINESS WIRE)--Nnamdi Njoku appointed President of Omnicell leading global operations & innovation strategy; Randall Lipps continues as CEO, Chairman of the Board.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.